Isodiol International Inc., (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)(the “Company” or “Isodiol”)a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a licensing agreement with Level Brands Inc. (NYSE American:LEVB), an innovative marketing and licensing company that provides bold, unconventional and socially responsible branding for leading businesses.

Under the agreement, Isodiol will work with Level Brands to develop consumer products for its business units, kathy ireland® Health & Wellness and Ireland Men One (I’M1), the company’s lifestyle brand for men.  Encore Endeavor One (EE1), Level Brands’ corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines.


“We look forward to benefitting from Kathy Ireland’s proven track record in product strategy and marketing,” said Marcos Agramont, President of Isodiol.  “Ms. Ireland has an uncanny sense of her consumers’ tastes and needs, which has led to their extraordinary loyalty and confidence in her products. Having brought over 17,000 diverse and popular products to market, she has captured the hearts and minds of millions of customers who actively and consistently support her brands.  Ms. Ireland will bring tremendous energy into this burgeoning field, and we are eager to work with her and the incredible team assembled at Level Brands.”

“Isodiol is an innovative, progressive and pioneering company,” said Kathy Ireland, Level Brands’ Chairman Emeritus and Chief Brand Strategist. “Their success in CBD products derived from hemp are 99%+ pure, bioactive and pharmaceutical grade. The products include body balm, tincture, skincare, nano-mist and functional beverages. One of the many responsibilities in this new venture is, for me personally, to serve as Educator in Chief about cannabidiol, and how it is used in Isodiol. This company is leading the strategy of appropriate uses of hemp derivatives, and Isodiol products are free of THC. It’s ironic that people find controversy in the powerfully useful hemp plant. Without THC, hemp has many natural and important uses, which are beneficial in countless ways. We need people to please understand, that hemp, without THC, is similar to a grape without fermentation. What the Isodiol team has done is, bring the best qualities of hemp-derived CBD to the market without any psychotropic element, whatsoever. This is the second product for kathy ireland® Health & Wellness, licensed by Level Brands, and we welcome the Isodiol team to our family at Level.”

“Level Brands is committed to exploring new and cutting-edge technologies and products and bringing them to the American market,” says Martin A. Sumichrast, CEO of Level Brands’.  “Isodiol is a pioneer and a leader in the commercialization of a 99%+ pure, Bioactive pharmaceutical-grade cannabinoid products derived from the hemp plant. We are excited to work with Isodiol on developing the highest quality hemp derivatives-based consumable and topical skin care products for kathy ireland® Health & Wellness and I’M1.”

kathy ireland® Health & Wellness, I’M1 and EE1 are led in marketing and creative by Stephen Roseberry, President and Chief Marketing Officer of kathy ireland® Worldwide (kiWW®), together with kiWW®’s Global Creative Director, Jon Carrasco.  I’M1 was co-founded by Kathy Ireland and Tommy Meharey – Marine, millennial father, global fashion model, concert producer, Vice President of kathy ireland® Weddings & Resorts, as well as the youngest Board of Directors member of kathy ireland® Worldwide.  EE1 was co-founded by Ireland and Nic Mendoza, heir to a family legacy with generations of extraordinary musical success. Mr. Mendoza is a certified sound specialist, with an emphasis on live performance, having toured with artists as diverse as Janet Jackson and Robin Thicke, and a producer of albums and musical theater.

The new Isodiol kathy ireland® Health & Wellness and I’M1 products are expected to debut in mid to late Spring 2018 and be available online and in select retail stores.  Level Brands is committed to social responsibility, with each partner, client, and licensee supporting its Millennium Development Goals to improve the condition of lives around the world.  Through this licensing agreement, Isodiol has made a corporate culture and financial commitment to support these goals with an emphasis on health and wellness.

Level Brands will receive an initial US$2 million payment in the form of Isodiol shares and initial cash payments of US$62,500 each due at execution of the licensing agreement and on June 30, 2018 . During the term of the agreement Level will also receive US$750,000 per quarter in the form of Isodiol shares and a 3% royalty on all gross sales of branded products. The release of Isodiol shares to Level shall be subject to a rolling thirty-month escrow following each issuance. The contract term is for an initial five years. Marketing materials were designed and filmed in December 2017 and both parties intend to finalize all points of the negotiations no later than January 31, 2018.

About Isodiol International Inc. (www.Isodiol.com)

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and aggressively continuing international expansion into Latin America, Asia and Europe.

About Level Brands, Inc. (www.LevelBrands.com)

Level Brands creates bold, unconventional and socially responsible branding for leading businesses. With a focus on corporate brand management and consumer products marketing art, beauty, fashion, health & wellness including the beverage space, entertainment, and real estate. Licensed brand marketing is at the core of the Level Brand businesses: Ireland Men One or I’M1, for millennial men and the women who love them; Encore Endeavor One or EE1, corporate brand management and producer of experiential entertainment events and products across multiple platforms; kathy ireland® Health & Wellness; Beauty & Pin-Ups, Level Brands’ hair care and disruptive women’s products brand.

Join Us On:
Facebook
: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
604-409-4409
marcos@isodiol.com
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Click here to connect with Isodiol International Inc., (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) for an Investor Presentation

Source: globenewswire.ca

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less